Neoadjuvant Pembrolizumab Not Tied to More AEs in Oral Cavity SCC

THURSDAY, Sept. 15, 2022 (HealthDay News) -- Among patients with local regionally advanced oral cavity squamous cell carcinoma, rates of postoperative adverse events appear to be similar for those receiving neoadjuvant pembrolizumab or standard-of-care treatment, according to a study published online Aug. 25 in JAMA Otolaryngology-Head & Neck Surgery.
Alice L. Tang, M.D., from the University of Cincinnati, and colleagues evaluated the incidence of postoperative adverse events in 32 treatment-naïve patients with advanced oral cavity cancer receiving neoadjuvant pembrolizumab versus matched controls.
The researchers found that postoperative adverse events in the 32 patients receiving pembrolizumab included lymphedema (63 percent), trismus (22 percent), return to operating room (22 percent), wound infection (22 percent), fistula (19 percent), wound dehiscence (13 percent), flap failure (9 percent), and hematoma (6 percent). Similar complications were seen in the control group, except for trismus (50 percent), which was greater by a difference of 28.1 percent in the control group.
"Neoadjuvant pembrolizumab does not appear to be associated with higher rates of adverse events in the setting of advanced head and neck cancer and does not appear to increase perioperative morbidity," the authors write.
One author disclosed financial ties to biotechnology companies, including Merck, the manufacturer of pembrolizumab.
Abstract/Full Text (subscription or payment may be required)
Was this page helpful?
Was this page helpful?
Was this page helpful?
Was this page helpful?
Related Posts
HPV Vaccination May Be Cutting Cervical Cancer Rates
WEDNESDAY, March 16, 2022 (HealthDay News) -- The recent decrease in the...
Handheld Device Used to Screen for A-Fib in Primary Care Setting
THURSDAY, March 24, 2022 (HealthDay News) -- A handheld single-lead...
Mom’s Exposure to Dirty Air in Pregnancy Could Harm a Toddler’s Development
THURSDAY, Jan. 26, 2023 (HealthDay News) -- A mother-to-be's exposure to air...
A Vaccine Against Deadly Fentanyl Might Be Near
THURSDAY, Nov. 17, 2022 (HealthDay News) -- Researchers report they have created...